BIOSENSE TECHNOLOGIES, INC.

Medtech · Acquired

Rapid phenotypic assay platform that measures antibiotic-induced cellular stress to determine bacterial susceptibility to antibiotics in minutes

Grants
$203K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
$86K
2 awards · Defense, Veterans Affairs
#536 of 4531 in medtech
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Defense · Dielectric Biological Sensor$61,118
Federal contractDepartment of Veterans Affairs · Catheters$24,731
Federal grantDepartment of Health and Human Services · Phase I · Rapid Phenotypic Antibiotic Susceptibility Testing$203,215
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
533Golden Helix, Inc.$93K—
534ZRT LABORATORY, LLC$92K—
535SYNTERMED INCORPORATED$88K—
536BIOSENSE TECHNOLOGIES, INC.$86K—
537ALLELE DIAGNOSTICS INC$84K—
538Caption Health$81K$69M
539Cleerly, Inc.$80K$266M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Method And Composition For Rapid Viability Testing Of Cellsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.